AVA ADR 001
Alternative Names: AVA-ADR-001Latest Information Update: 20 Jun 2023
At a glance
- Originator Avammune Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action ADAR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Apr 2023 Preclinical trials in Solid tumours in USA (unspecified route) before April 2023 (Avammune Therapeutics pipeline, June 2023)
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)